Rapid CommunicationSR141716A is an inverse agonist at the human cannabinoid CB1 receptor
Section snippets
Acknowledgements
This work was supported in part by grants from the Arizona Disease Control Research Commission and the National Institute of Drug Abuse.
References (6)
- et al.
SR 141716A, a cannabinoid receptor antagonist, produces hyperalgesia in untreated mice
Eur. J. Pharmacol.
(1997) - et al.
SR141716A, a potent and selective antagonist of the brain cannabinoid receptor
FEBS Lett.
(1994) - et al.
Cannabinoid receptor stimulation of guanosine-5′-O-(3-[]thio)triphosphate binding in rat brain membranes
Life Sci.
(1996)
Cited by (241)
Rimonabant, a potent CB1 cannabinoid receptor antagonist, is a Gα<inf>i/o</inf> protein inhibitor
2018, NeuropharmacologyCitation Excerpt :The inhibitory effect of rimonabant was observed at concentrations of GDP and NaCl that allow a constant and significant reduction in basal [35S]GTPγS, as previously reported (Sim-Selley et al., 2001). However, in contrast to previous studies (Landsman et al., 1997; MacLennan et al., 1998; Howlett et al., 2011), rimonabant at 10 and 100 nM concentrations failed to inhibit basal [35S]GTPγS binding (100.3% ± 2 and 93% ± 5 over basal activity, respectively). The effect of rimonabant on the stimulation of [35S]GTPγS binding by baclofen and the D2 receptor agonist quinpirole was measured in rat and mouse cortical membranes.
Analysis of the pharmacological properties of JWH-122 isomers and THJ-2201, RCS-4 and AB-CHMINACA in HEK293T cells and hippocampal neurons
2018, European Journal of PharmacologyPeripheral modulation of the endocannabinoid system in metabolic disease
2018, Drug Discovery TodayCitation Excerpt :Furthermore, CB1-deficient mice have increased energy expenditure [39]; and even following consumption of a high-fat diet (HFD) (49% of energy as fat) CB1-deficient mice do not become obese [38]. Rimonabant, the most widely studied antagonist, has been shown to act as a CB1 antagonist and inverse agonist [40,41]. Rimonabant was developed and marketed for the treatment of obesity but was withdrawn from the market in 2008 owing to severe psychological side effects.
The endocannabinoid system as a target for addiction treatment: Trials and tribulations
2017, NeuropharmacologyCannabinoids as hippocampal network administrators
2017, NeuropharmacologySignaling and Regulation of the Cannabinoid CB1 Receptor
2017, Handbook of Cannabis and Related Pathologies: Biology, Pharmacology, Diagnosis, and Treatment